{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T08:10:04Z","timestamp":1714896604312},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0055017","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T00:37:46Z","timestamp":1359419866000},"page":"e55017","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Application of a Stochastic Modeling to Assess the Evolution of Tuberculous and Non-Tuberculous Mycobacterial Infection in Patients Treated with Tumor Necrosis Factor Inhibitors"],"prefix":"10.1371","volume":"8","author":[{"given":"Elena","family":"Agliari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Asti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Barra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Scrivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Valesini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"D Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"D Lee","year":"2001","journal-title":"The Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"E Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0192-0561(94)00092-3","article-title":"TNF alpha blockade in rheumatoid arthritis: rationale, clinical out-comes and mechanisms of action","volume":"17","author":"M Elliott","year":"1995","journal-title":"Int J Immunopharmacol"},{"key":"ref5","first-page":"1","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"P Tak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management","volume":"3","author":"M Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"R Wallis","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"R Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/art.23285","article-title":"Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade","volume":"58","author":"R Wallis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"R Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/517519","article-title":"Neutralization of tumor necrosis factor (TNF) by antibody but not tnf receptor fusion molecule exacerbates chronic murine tuberculosis","volume":"195","author":"H Plessner","year":"2007","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.immuni.2008.06.011","article-title":"Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death","volume":"29","author":"H Clay","year":"2008","journal-title":"Immunity"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.27271","article-title":"TNF neutralization results in disseminated disease during acute and latent M. tuberculosis infection with normal granuloma structure","volume":"62","author":"P Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10067-005-1135-4","article-title":"A case of tuberculous meningoencephalitis in a patient with Behcet\u2019s disease","volume":"25","author":"A Iliopoulos","year":"2006","journal-title":"Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0002-9343(02)01205-6","article-title":"Exacerbation of tuberculosis enteritis after treatment with infliximab","volume":"113","author":"E Liberopoulos","year":"2002","journal-title":"Am J Med"},{"key":"ref17","first-page":"77","article-title":"Tuberculous peritonitis during infliximab therapy","volume":"66","author":"JC Verhave","year":"2008","journal-title":"Neth J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analysis of adalimumab (humira\u00e6) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"M Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s10067-012-2049-6","article-title":"Serial interferon- release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents","volume":"31","author":"R Scrivo","year":"2012","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Scrivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, <etal>et al<\/etal>. (2012) Mycobacterial IFN-gamma release variations during long-term treatment with TNF blockers: lack of correlation with clinical outcome. J Rheumatol (in press).","DOI":"10.3899\/jrheum.120688"},{"key":"ref21","unstructured":"Wagner D, Young L (2003) Nontuberculous mycobacteria infections: a clinical review. Infection 31."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ats\/idsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"D Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-\u03b1 therapy","volume":"15","author":"K Winthrop","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-TNF and other newly approved biological therapies; case-finding via the emerging infectious network","volume":"46","author":"K Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4049\/jimmunol.160.2.943","article-title":"TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation","volume":"160","author":"J Peschon","year":"1998","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1371\/journal.pcbi.0030194","article-title":"Differences in reactivation of tuberculosis induced from anti-tnf treatments are based on bioavailability in granulomatous tissue","volume":"3","author":"S Marino","year":"2007","journal-title":"PLoS Computational Biology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.1103298","article-title":"Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability","volume":"188","author":"M Fallahi-Sichani","year":"2012","journal-title":"The J Immun"},{"key":"ref28","unstructured":"Pearson RK (1952) Exploring Data in Engineering, the Sciences, and Medicine. Oxford University Press."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1164\/rccm.200808-1258ED","article-title":"The importance of nontubercolous mycobacterial lung disease","volume":"178","author":"M Iseman","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.plrev.2008.07.001","article-title":"From the mathematical kinetic, and stochastic game theory, to modelling mutations, onset, progression and immune competition of cancer cells","volume":"5","author":"N Bellomo","year":"2008","journal-title":"Phys Life Rev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/17513758.2012.704083","article-title":"Can persistent Epstein-Barr virus infection induce chronic fatigue syndrome as a Pavlov reflex of the immune response","volume":"6","author":"E Agliari","year":"2012","journal-title":"J Biol Dyn"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jtbi.2011.07.027","article-title":"A thermodynamic perspective of immune capabilities","volume":"287","author":"E Agliari","year":"2011","journal-title":"J Theor Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.plrev.2005.03.003","article-title":"Models of stochastic gene expression","volume":"2","author":"J Paulsson","year":"2005","journal-title":"Phys Life Rev"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.plrev.2009.12.001","article-title":"Evolution of immune system from self not-self to danger to artificial immune system","volume":"7","author":"E Cooper","year":"2010","journal-title":"Phys Life Rev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0272-5231(02)00014-X","article-title":"Nontuberculous mycobacteria in the environment","volume":"23","author":"JI Falkinham","year":"2002","journal-title":"Clin Chest Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0041-3879(83)90021-1","article-title":"The risk of tuberculous infection in the Netherlands from 1967 to 1979","volume":"64","author":"I Sutherland","year":"1983","journal-title":"Tubercle"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e7749","DOI":"10.1371\/journal.pone.0007749","article-title":"Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa","volume":"4","author":"K Shanaube","year":"2009","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1086\/516495","article-title":"Estimation of the annual risk of tuberculosis infection for white men in the United States","volume":"175","author":"T Daniel","year":"1997","journal-title":"J Infect Dis"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0055017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T07:29:20Z","timestamp":1714894160000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0055017"}},"subtitle":[],"editor":[{"given":"Pere-Joan","family":"Cardona","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0055017","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,28]]}}}